Povidone iodine: properties, mechanisms of action and role in infection control and staphylococcus aureus decolonization

Lepelletier, Didier, Maillard, Jean Yves ORCID: https://orcid.org/0000-0002-8617-9288, Pozzetto, Bruno and Simon, Anne 2020. Povidone iodine: properties, mechanisms of action and role in infection control and staphylococcus aureus decolonization. Antimicrobial Agents and Chemotherapy 64 (9) , e00682-20. 10.1128/AAC.00682-20

Preview

PDF - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (767kB) | Preview

Abstract

Nasal decolonization is an integral part of the strategies used to control and prevent the spread of methicillin-resistant Staphylococcus aureus (MRSA) infections. The two most commonly used agents for decolonization are intranasal mupirocin 2% ointment and chlorhexidine wash but the increasing emergence of resistance and treatment failure has underscored the need for alternative therapies. This article discusses povidone iodine (PVP-I) as an alternative decolonization agent and is based on literature reviewed during an Expert's workshop on resistance and MRSA decolonization. When compared to chlorhexidine and mupirocin, respectively, PVP-I 10% and 7.5% solution had rapid and superior bactericidal activity against MRSA in in vitro and ex vivo studies. Notably, PVP-I 10% and 5% solutions were also active against both chlorhexidine-resistant and mupirocin-resistant strains, respectively. Unlike chlorhexidine and mupirocin, available reports have not observed a link between PVP-I and the induction of bacterial resistance or cross-resistance to antiseptics and antibiotics. These pre-clinical findings also translate into clinical decolonization, where intranasal PVP-I significantly improved the efficacy of chlorhexidine wash and was as effective as mupirocin in reducing surgical site infection (SSI) in orthopedic surgery. Overall, these qualities of PVP-I make it a useful alternative decolonizing agent for the prevention of S. aureus infections, but additional experimental and clinical data are required to further evaluate the use of PVP-I in this setting.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Publisher:	American Society for Microbiology
ISSN:	0066-4804
Date of First Compliant Deposit:	8 July 2020
Date of Acceptance:	17 June 2020
Last Modified:	04 Dec 2024 06:15
URI:	https://orca.cardiff.ac.uk/id/eprint/133239

Citation Data

Cited 35 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item